Show simple item record

dc.contributor.authorWu, E.en_US
dc.contributor.authorKover, A.en_US
dc.contributor.authorLoch, J.en_US
dc.contributor.authorRosenberg, L.en_US
dc.contributor.authorSemus, S.en_US
dc.contributor.authorVerhoest, P.en_US
dc.contributor.authorGordon, J.en_US
dc.contributor.authorMachulskis, A.en_US
dc.contributor.authorMcCreedy, S.en_US
dc.contributor.authorZongrone, J.en_US
dc.contributor.authorBlosser, J.en_US
dc.date.accessioned2006-07-19T20:06:31Zen_US
dc.date.available2006-07-19T20:06:31Zen_US
dc.date.issued1996-11-05en_US
dc.identifier.citationBioorganic and Medicinal Chemistry Letters 6N21 (1996) 2525-2530en_US
dc.identifier.issn0960-894Xen_US
dc.identifier.urihttp://hdl.handle.net/1850/2255en_US
dc.description.abstractTo improve receptor binding affinity and to investigate functional selectivity of 2,8-dimethyl-1-oxa-8- azaspiro[4.5]decan-3-one acetylhydrazone 2 at muscarinic receptor subtypes, a series of acylhydrazones A was synthesized. The SAR indicates that the binding affinity in the pirenzepine assay (M1) correlates well with lipophilicity. Intrinsic activity (30% of carbachol response) of agonists at M1 remains unchanged. Compounds with n = 0 and 6, where X = NHCO(CH2)nMe, did not inhibit cAMP formation in rat heart membrane (M2). Most of the compounds are more efficacious at the M3 receptor than at M1. The results suggest that the M1 and M3 receptors can better tolerate bulky and long chained substituents than the M2 receptor.en_US
dc.format.extent37365 bytesen_US
dc.format.mimetypeapplication/pdfen_US
dc.language.isoen_USen_US
dc.publisherElsevier: Bioorganic and Medicinal Chemistry Lettersen_US
dc.subjectReceptor binding affinityen_US
dc.titleAcylhydrazones as M1/M3 selective muscarinic agonistsen_US
dc.typeAbstracten_US
dc.identifier.urlhttp://dx.doi.org/10.1016/0960-894X(96)00471-4


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record